PCSK9抑制剂与急性损伤之间的关联:一个药监测研究
1Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Frontiers in pharmacology
|August 16, 2024
概括
用于降低脂质的PCSK9抑制剂可能对急性损伤 (AKI) 有保护作用. 这项药监测研究分析了FAERS数据,表明即使与其他药物同时服用,也可能有潜在的益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
背景情况:
- PCSK9抑制剂是新的降脂药物,在慢性脏病中具有既定的益处.
- 最近的病例报告表明PCSK9抑制剂与急性损伤 (AKI) 之间存在潜在的关联.
研究的目的:
- 为了研究PCSK9抑制剂 (evolocumab,alirocumab) 和AKI之间的关系.
- 为了澄清PCSK9抑制剂关于功能的安全概况.
主要方法:
- 使用FDA不良事件报告系统 (FAERS) 数据库 (2015年第三季度2022年第四季度) 的药监测研究.
- 使用不相称性分析来确定与PCSK9抑制剂相关的AKI事件.
主要成果:
- 对144,341份不良事件报告的分析确定了444例疑似AKI病例,其中evolocumab和172例是alirocumab.
- 埃沃洛库马布对男性的AKI产生更大的影响 (ROR 1.4).
- 同时使用某些药物,如罗西米德和潘托普拉,显示出特定的ROR,表明潜在的相互作用或保护作用.
结论:
- PCSK9抑制剂可能具有针对AKI的潜在保护作用.
- 这种保护作用即使与其他潜在的毒药物同时使用,似乎也是一致的.
相关概念视频
Pharmacovigilance
797
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
797
Renal Failure: Dose Adjustments
71
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
71
Factors Affecting Renal Clearance: Renal Impairment
63
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
63
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
196
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
196
Antihypertensive Drugs: Direct Renin Inhibitors
513
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
513
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
52
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
52


